Hsbc Holdings PLC Decreases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Hsbc Holdings PLC decreased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 17.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,378 shares of the specialty pharmaceutical company’s stock after selling 493 shares during the quarter. Hsbc Holdings PLC’s holdings in Jazz Pharmaceuticals were worth $292,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Fuller & Thaler Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock valued at $165,245,000 after purchasing an additional 391,660 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Jazz Pharmaceuticals by 141.5% during the 1st quarter. Wellington Management Group LLP now owns 100,962 shares of the specialty pharmaceutical company’s stock valued at $12,534,000 after purchasing an additional 59,159 shares during the last quarter. Northern Trust Corp increased its position in shares of Jazz Pharmaceuticals by 0.8% during the 1st quarter. Northern Trust Corp now owns 525,163 shares of the specialty pharmaceutical company’s stock valued at $65,199,000 after purchasing an additional 3,967 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Jazz Pharmaceuticals by 411.1% during the 1st quarter. Brooklyn Investment Group now owns 552 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 444 shares during the last quarter. Finally, Raymond James Financial Inc. increased its position in shares of Jazz Pharmaceuticals by 67.9% during the 1st quarter. Raymond James Financial Inc. now owns 155,066 shares of the specialty pharmaceutical company’s stock valued at $19,251,000 after purchasing an additional 62,719 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 2.8%

JAZZ stock opened at $128.02 on Friday. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The company has a market capitalization of $7.77 billion, a price-to-earnings ratio of -19.02, a PEG ratio of 8.17 and a beta of 0.24. The business has a 50 day simple moving average of $116.23 and a two-hundred day simple moving average of $117.08.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Royal Bank Of Canada upped their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. The Goldman Sachs Group boosted their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $178.67.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.